AstraZeneca/Oxford Covid-19 vaccine trial can resume

• The FDA has concluded its probe of two cases of a possible neurological side effect, and this afternoon told AstraZeneca (NASDAQ:AZN) it may resume the U.S. trial of its Covid-19 vaccine candidate, reports the WSJ.
• The FDA concluded that the vaccine was not responsible for the issues, though it could not rule out a link, according to the story.
• Prior to the trial halt, the vaccine had been one of the furthest along in development, and was perhaps on track for approval by year-end.
• It was reported earlier this week that AZN's trial (as well as J&J's) was on track to get the go-ahead to resume.
• https://seekingalpha.com/news/3625433-astrazeneca-oxford-covidminus-19-vaccine-trial-can-resume-wsj